The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
 
Anjali Rohatgi
No Relationships to Disclose
 
Ryan Campbell Massa
No Relationships to Disclose
 
William E. Gooding
No Relationships to Disclose
 
Tullia C. Bruno
No Relationships to Disclose
 
Dario Vignali
Leadership - F-Star; Tizona Therapeutics, Inc.; Werewolf Therapeutics
Stock and Other Ownership Interests - Oncorus; Tizona Therapeutics, Inc.; TTMS; Werewolf Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; G1 Therapeutics; Innovent Biologics; Kronos Bio
Research Funding - Astellas Pharma; Bristol-Myers Squibb; TTMS
Patents, Royalties, Other Intellectual Property - Astellas Pharma; Bristol-Myers Squibb; Tizona Therapeutics, Inc.
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; F-Star; Tizona Therapeutics, Inc.; Werewolf Therapeutics
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Elsevier; Immunocore; Immunocore (Inst); Iovance Biotherapeutics; Merck (Inst); Novartis
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)